EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in Advanced NSCLC
Edward B. Garon, MD, MS, reviews data from the EVOKE-02 study, and the panel offers their thoughts on antibody-drug conjugates for the treatment of advanced NSCLC.
Expert Perspectives on the Results of the TROPION-Lung01 Study in NSCLC
The expert panel reviews the results from the TROPION-Lung01 study and discusses how the data can inform treatment decisions for patients with previously treated NSCLC.
TROPION-Lung01: Dato-DXd in Previously Treated Advanced NSCLC
Solange Peters, MD, PhD, reviews key data from TROPION-Lung01 investigating datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non–small cell lung cancer.
NSCLC: PD-L1 Expression and Treatment Decision-Making
Clinical insights on how the level of PD-L1 expression informs treatment decisions for patients with non–small cell lung cancer.
The Role of CTLA-4 Inhibitors in NSCLC
Experts on non–small cell lung cancer discuss the role of CTLA-4 inhibitors in the NSCLC treatment landscape.
First-Line Treatment Strategies for Advanced Non–Small Cell Lung Cancer
A panel of thoracic medical oncologists provide an overview of first-line treatment strategies for advanced non–small cell lung cancer (NSCLC).
Dr. Sabari on the EVOKE-02 Trial With Sacituzumab Govitecan in NSCLC
Joshua K. Sabari, MD, discusses the ongoing phase 2 EVOKE-2 trial investigating sacituzumab govitecan-hziy in non– small cell lung cancer; emerging data on antibody-drug conjugates in the second– or first-line treatment setting; and the planned phase 3 EVOKE-03 trial of sacituzumab govitecan plus pembrolizumab as a frontline treatment.
Clinical Pearls and Closing Thoughts on NSCLC Treatment Landscape
Closing out their discussion on biomarker testing and targeted therapies in non–small cell lung cancer, the panel of expert oncologists share clinical pearls and thoughts on the evolving treatment landscape.
Emerging Targets in Non–Small Cell Lung Cancer
Julie R. Brahmer, MD, details emerging targets in non–small cell lung cancer and the outlook for the future of treatment.
Treating MET Exon 14 NSCLC
The focus turns to therapeutic strategies for treating MET exon 14 non–small cell lung cancer.
Approach to Treating Patients with NSCLC and RET Fusions
Experts on non–small cell lung cancer share their approaches to treating patients who have RET fusions and review updates on selpercatinib and pralsetinib.
Treatment of NTRK Fusions in NSCLC
Julie R. Brahmer, MD, and Joshua K. Sabari, MD, review recent data on entrectinib and larotrectinib for the treatment of patients with NSCLC with NTRK fusions.
Choosing Between ALK Inhibitors in the Treatment of NSCLC
The expert panel discusses factors that influence treatment decisions when choosing appropriate therapy for patients with ALK-rearranged NSCLC.
Emerging Treatment Options for Patients with NSCLC with ALK Rearrangements
Experts on non–small cell lung cancer discuss recent data on brigatinib and lorlatinib for the treatment of patients with ALK rearrangements.
Is There a Role for Immunotherapy in Patients with KRAS G12C-Mutant NSCLC and STK11 or KEAP1 Co-Mutations?
Luis Raez, MD, offers insights on how co-mutations in STK11 or KEAP1 impact the use of immunotherapies in KRAS G12C–mutant non–small cell lung cancer.
Adagrasib for Patients with KRAS G12C–Mutant NSCLC
Joshua K. Sabari, MD, discusses adagrasib as a treatment of patients with NSCLC with KRAS G12C mutations, and provides insight on treating patients who have progressed on prior KRAS G12C inhibitors.
Sotorasib in the Treatment of KRAS G12C–Mutant NSCLC
Expert panelists review the CodeBreaK trials focused on sotorasib in the treatment of patients with KRAS G12C-mutant non–small cell lung cancer.
NSCLC With Uncommon EGFR Mutations: First-Generation EGFR TKIs and Role of Immunotherapy
Shared insight on the use of first-generation EGFR tyrosine kinase inhibitors and the role of immunotherapy in treating patients with NSCLC with uncommon EGFR mutations.
Choosing Treatments for Patients with NSCLC with Uncommon EGFR Mutations
Julie R. Brahmer, MD, discusses treatment considerations when choosing between afatinib and osimertinib in patients with NSCLC with rare EGFR mutations.
Treatment Options for Patients with NSCLC with EGFR Mutations
Key opinion leaders on non–small cell lung cancer review treatment options for patients with EGFR mutations.
Strategies to Improve Biomarker Testing in NSCLC
Experts on non–small cell lung cancer discuss strategies to improve molecular testing and opportunities for community physicians to reach out to expert oncologists for clinical insights.
Biomarker Testing Patterns in Academic and Community Settings Treating NSCLC
Antonia Sepulveda, MD, PhD, an expert on NSCLC, outlines discrepancies in molecular testing between academic and community settings.
NSCLC: Biomarker Testing Strategies and Turnaround Time
Focused discussion on tissue testing and the effect of turnaround time on NSCLC treatment and molecular testing strategies.
Liquid vs Tissue Biopsies in NSCLC
Expert oncologists compare the logistics and sensitivities of liquid and tissue biopsies in the treatment of non–small cell lung cancer.
Biomarker Testing in Non-Small Cell Lung Cancer
A panel of experts on the treatment of non–small cell lung cancer (NSCLC) discuss the role of biomarker testing and review testing strategies.
Dr Sabari on Preliminary Data From a Phase 1 Study of LY3537982 in KRAS G12C–mutant Advanced Solid Tumors
Joshua K. Sabari, MD, discusses key findings from the phase 1 LOXO-RAS-20001 study of the KRAS G12C inhibitor LY3537982 in KRAS G12C–mutant advanced solid tumors.
KRAS G12C–Mutated NSCLC: Real-World Implications of Novel Targeted Therapy
Closing out their review of treatment options for KRAS G12C–mutated NSCLC, expert oncologists look toward future utilization of novel targeted agents in this setting.
2L KRAS Inhibitors for Patients With KRAS G12C–Mutated NSCLC
Centering discussion on KRAS inhibitors and associated clinical trials, Martin Dietrich, MD, PhD, and Joshua Sabari, MD, detail the second-line management of KRAS G12C–mutated non–small cell lung cancer.
Non–Small Cell Lung Cancer: Selecting 1L Therapy for Patients With KRAS G12C Mutations
Key opinion leaders identify the first-line treatment armamentarium for patients with KRAS G12C–mutated non–small cell lung cancer.
Non–Small Cell Lung Cancer: Informing 1L Therapy Selection With Molecular Testing
A brief review of how results from adequate molecular testing may help to inform the first-line management of non–small cell lung cancer.
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512